門脈圧亢進症の診療ガイド　2022

出版社： 文光堂
著者：
発行日： 2022-09-28
分野： 臨床医学：内科  >  消化器一般
ISBN： 9784830621123
電子書籍版： 2022-09-28 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

3,300 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,300 円(税込)

購入する

商品紹介

非代償性肝硬変の主要な死因の一つである門脈圧亢進症．本疾患をよく理解し，対応することは全ての肝臓専門医に求められている重要事項といえる．本書は，肝硬変などによる門脈圧亢進症の治療に肝臓専門医が対峙する際の，“より具体的な治療適応の指針”を示すことを目的としている．「肝硬変診療ガイドライン」や「門脈圧亢進症取扱い規約」，「門脈圧亢進症診療マニュアル」では記載しきれなかった診療上の重要事項が満載の実践的1冊．

目次

  • 第1章　門脈圧亢進症の概要と分類
    　概要と分類

    第2章　門脈圧亢進症の診断
    　1．血液生化学(血小板・総胆汁酸・アンモニア/M2BPGi/オートタキシン)
    　2．内視鏡検査
    　3．超音波（エラストグラフィを除く）
    　4．造影CT
    　5．門脈圧測定
    　6．エラストグラフィ（超音波エラストグラフィ/MRエラストグラフィ）

    第3章　門脈圧亢進症の治療適応と治療法の選択
    　1．消化管静脈瘤
    　　　(1)食道胃噴門部静脈瘤治療の適応と選択
    　　　(2)孤立性胃静脈瘤治療の適応と選択
    　　　(3)異所性静脈瘤治療の適応と選択
    　　　(4)再発時薬物療法
    　2．門脈血栓症
    　3．肝性脳症
    　4．難治性腹水
    　5．門脈圧亢進症性胃症（PHG）
    　6．血小板減少
    　7．PoPH
    　8．門脈圧亢進症の背景肝硬変への原因治療
    　9．門脈圧亢進症に対する肝移植の適応

    第4章　各種原因における門脈圧亢進症への対策
    　1．バッド・キアリ症候群
    　2．チロシンキナーゼ阻害薬（TKI）の門脈圧亢進症への影響
    　3．オキサリプラチンによる肝中心静脈閉塞症（VOD）/肝類洞閉塞性症候群(SOS)
    　4．造血幹細胞移植後のVOD/SOSとデフィブロチド　

    第5章　今後の課題-Where is “Point of no return”を求めて
    　SVR後肝硬変のPoint of no returnは門脈圧亢進症の存在か？

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 門脈圧亢進症の概要と分類

P.4 掲載の参考文献
1) 日本門脈圧亢進症学会 (編) : 門脈圧亢進症取扱い規約, 第3版, 金原出版, 20, 2013
 
2) 日本門脈圧亢進症学会 (編) : 門脈圧亢進症取扱い規約, 第3版, 金原出版, 3-5, 2013
 
3) 滝川一ほか : 門脈血行異常症ガイドライン 2018年改訂版 (2018年12月13日 Version), 厚生労働科学研究費補助金 (難治性疾患政策研究事業) 「難治性の肝・胆道疾患に関する調査研究」班 : 門脈血行異常症分科会, 2018
 
4) 泉並木 (監) : 肝硬変の成因別実態 2014, 医学図書出版, 148, 2015
 
5) Kokubu S : Diagnosis of portal vein thrombosis. In Obara K ed, Clinical Investigation of Portal Hypertension, Springer, 481-484, 2019
 
6) Dignan FL et al : BCSH/BSBMT guideline : diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol 163 : 444-457, 2013
PubMed

第2章 門脈圧亢進症の診断

P.7 掲載の参考文献
1) 直江秀昭ほか : 門脈圧亢進症の診断. 日消誌 116 : 374-385, 2019
Medical*Online
2) Berzigotti A et al : Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology 144 : 102-111.e1, 2013
 
3) 日本消化器病学会, 日本肝臓学会 (編) : NAFLD/NASH診療ガイドライン 2020改訂第2版, 南江堂, 2020
 
4) Wu PS et al : Mac-2 binding protein glycosylation isomer is a potential biomarker to predict portal hypertension and bacterial infection in cirrhotic patients. PLoS One 16 : e0258589, 2021
PubMed
5) Shao X et al : Usefulness of autotaxin for the complications of liver cirrhosis. World J Gastroenterol 26 : 97-108, 2020
PubMed
6) Shirabe K et al : Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis : more than a biomarker of liver fibrosis. J Gastroenterol 53 : 819-826, 2018
PubMed
P.10 掲載の参考文献
1) 日本門脈圧亢進症学会 (編) : 門脈圧亢進症取扱い規約, 第3版, 金原出版, 2013
 
2) Garcia-Tsao G et al : Portal hypertensive bleeding in cirrhosis : Risk stratification, diagnosis, and management : 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 65 : 310-335, 2017
 
3) European Association for the Study of the Liver : EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 69 : 406-460, 2018
 
4) Merkel C et al : Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria. J Hepatol 52 : 45-53, 2010
PubMed
5) Sarin SK et al : Prevalence, classification and natural history of gastric varices : a long-term follow-up study in 568 portal hypertension patients. Hepatology 16 : 1343-1349, 1992
PubMed
6) Kim T et al : Risk factors for hemorrhage from gastric fundal varices. Hepatology 25 : 307-312, 1997
PubMed
P.12 掲載の参考文献
1) 日本消化器がん検診学会, 日本超音波医学会, 日本人間ドック学会 : 腹部超音波検診判定マニュアル改訂版 (2021年). https://www.jsgcs.or.jp/files/uploads/manual2021.pdf (閲覧2022年7月)
 
2) 浅野朗ほか : 内視鏡的硬化療法 (EIS) 前後の左胃静脈 (LGV) 血行動態-体外式カラードプラ超音波断層法 (CD-US) による検討-. 肝臓 40 : 205-216, 1999
 
P.14 掲載の参考文献
1) Yoshiji H et al : Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res 51 : 725-749, 2021
PubMed
2) 近森文夫ほか : 胃静脈瘤の血行動態と治療. 日門亢会誌 8 : 115-122, 2002
 
3) Nardelli S et al : Relevance of spontaneous portosystemic shunts detected with CT in patients with cirrhosis. Radiology 299 : 133-140, 2021
PubMed
4) 猪瀬正 : 肝脳変性疾患の一特殊型. 精神誌 51 : 53-76, 1950
 
P.17 掲載の参考文献
1) 近森文夫 : 門脈圧とそのゼロ点. 日門亢会誌 24 : 17-22, 2018
 
2) Yamamoto A et al : Utility of minimally invasive measurement of hepatic venous pressure gradient via the peripheral antecubital vein. Gut 70 : 1199-1201, 2021
 
3) Garcia-Tsao G et al : Portal hypertensive bleeding in cirrhosis : Risk stratification, diagnosis, and management : 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 65 : 310-335, 2017
 
4) Albilllos A et al : Classification of cirrhosis : the clinical use of HVPG measurements. Dis Markers 31 : 121-128, 2011
PubMed
5) Suk KT : Hepatic venous pressure gradient : clinical use in chronic liver disease. Clin Mol Hepatol 20 : 6-14, 2014
PubMed
6) Chikamori F et al : Stepwise partial splenic embolization for portal hypertension based on a new concept : Splanchnic caput Medusae. Radiol Case Rep 16 : 564-570, 2020
PubMed
P.21 掲載の参考文献
1) You MW et al : Meta-analysis for the diagnostic performance of transient elastography for clinically significant portal hypertension. Ultrasound Med Biol 43 : 59-68, 2017
PubMed
2) de Franchis R : Expanding consensus in portal hypertension : Report of the Baveno VI Consensus Workshop : Stratifying risk and individualizing care for portal hypertension. J Hepatol 63 : 743-752, 2015
PubMed
3) Thiele M et al : 2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis : An individual patient data meta-analysis. Liver Int 40 : 1435-1446, 2020
PubMed
4) Singh R et al : Accuracy of liver and spleen stiffness on magnetic resonance elastography for detecting portal hypertension : a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 32 : 237-245, 2021
PubMed
5) Sun HY et al : Usefulness of MR elastography for predicting esophageal varices in cirrhotic patients. J Magn Reson Imaging 39 : 559-566, 2014
PubMed
6) Matsui N et al : Magnetic resonance elastography increases usefulness and safety of non-invasive screening for esophageal varices. J Gastroenterol Hepatol 33 : 2022-2028, 2018
PubMed
7) Ma X et al : Spleen stiffness is superior to liver stiffness for predicting esophageal varices in chronic liver disease : A meta-analysis. PLoS One 11 : e0165786, 2016
PubMed
8) Hu X et al : Diagnostic accuracy of spleen stiffness to evaluate portal hypertension and esophageal varices in chronic liver disease : a systematic review and meta-analysis. Eur Radiol 31 : 2392-2404, 2021
PubMed
9) Shin SU et al : Prediction of esophageal varices in patients with cirrhosis : usefulness of three-dimensional MR elastography with echo-planar imaging technique. Radiology 272 : 143-153, 2014
PubMed
10) Nagai K et al : Gastroesophageal varices evaluation using spleen-dedicated stiffness measurement by vibration-controlled transient elastography. JGH Open 6 : 11-19, 2021
PubMed
11) Mandorfer M et al : Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol 65 : 692-699, 2016
PubMed
12) Takuma Y et al : Changes in liver and spleen stiffness by virtual touch quantification technique after balloon-occluded retrograde transvenous obliteration of gastric varices and exacerbation of esophageal varices : A preliminary study. Ultraschall Med 41 : 157-166, 2020
PubMed
13) 滝川一ほか : 門脈血行異常症ガイドライン 2018年改訂版 (2018年12月13日 Version), 厚生労働科学研究費補助金 (難治性疾患政策研究事業) 「難治性の肝・胆道疾患に関する調査研究」班 : 門脈血行異常症分科会, 2018
 

第3章 門脈圧亢進症の治療適応と治療法の選択

P.41 掲載の参考文献
1) D'Amico G et al : The treatment of portal hypertension : a meta-analytic review. Hepatology 22 : 332-354, 1995
PubMed
2) Garcia-Tsao G : Current management of the complications of cirrhosis and portal hypertension : variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 120 : 726-748, 2001
PubMed
3) Sangiovanni A et al : The natural history of compensated cirrhosis due to hepatitis C virus : A 17-year cohort study of 214 patients. Hepatology 43 : 1303-1310, 2006
PubMed
4) 日本消化器内視鏡学会 (監) : 消化器内視鏡ガイドライン 第3版, 医学書院, 215-233, 2006
 
5) 日本門脈圧亢進症学会 (編) : 門脈圧亢進症取扱い規約, 第3版, 金原出版, 2013
 
6) Garcia-Tsao G et al : Portal hypertensive bleeding in cirrhosis : Risk stratification, diagnosis, and management : 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 65 : 310-335, 2017
 
7) European Association for the Study of the Liver : EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 69 : 406-460, 2018
 
8) 日本消化器病学会, 日本肝臓学会 (編) : 肝硬変診療ガイドライン 2020 改訂第3版, 南江堂, 51, 2020
 
9) Villanueva C et al : Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Gastroenterology 137 : 119-128, 2009
PubMed
10) Garcia-Tsao G et al : Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 362 : 823-832, 2010
PubMed
11) Zhao Y et al : Observation of immediate and mid-term effects of partial spleen embolization in reducing hepatic venous pressure gradient. Medicine (Baltimore) 98 : e17900, 2019
PubMed
12) Ishikawa T et al : Splenic non-infarction volume determines a clinically significant hepatic venous pressure gradient response to partial splenic embolization in patients with cirrhosis and hypersplenism. J Gastroenterol 56 : 382-394, 2021
PubMed
13) 入澤篤志ほか : 孤立性胃静脈瘤に対する予防的内視鏡的硬化療法の適応-出血と再発の予知-. 日門食会誌 4 : 229-234, 1998
 
14) 上嶋昌和ほか : 孤立性胃静脈瘤に対する予防的治療の適応基準-経過観察例による検討-. 日門亢会誌 17 : 145-147, 2011
 
15) 小原勝敏 : 食道・胃静脈瘤の内視鏡治療 : 38年間の軌跡. 日門亢会誌 27 : 16-24, 2021
 
16) 日本消化器病学会, 日本肝臓学会 (編) : 肝硬変診療ガイドライン 2020 改訂第3版, 南江堂, 64, 2020
 
17) Luo X et al : Endoscopic cyanoacrylate injection versus balloon-occluded retrograde transvenous obliteration for prevention of gastric variceal bleeding : A randomized controlled trial. Hepatology 74 : 2074-2084, 2021
PubMed
18) Wakatsuki et al : Analysis of prognostic factors in patients with gastric varices after endoscopic treatment. Dig Endosc 21 : 232-238, 2009
PubMed
19) Irisawa A et al : Endoscopic ultrasound-guided coil deployment with sclerotherapy for isolated gastric varices : Case series of feasibility, safety, and long-term follow-up. Dig Endosc 32 : 1100-1104, 2020
PubMed
20) 入澤篤志ほか : Interventional EUS 最近の進歩 : 血管内治療の現状と今後の展望. 日消誌 117 : 1053-1061, 2020
 
21) 金川博史ほか : バルーン下逆行性経静脈的塞栓術 (Balloon-occluded retrograde transvenous obliteration ; B-RTO) による胃静脈瘤治療. 肝臓 32 : 442, 1991
 
22) Araki T et al : Balloon-occluded retrograde transvenous obliteration of gastric varices from unconventional systemic veins in the absence of gastrorenal shunts. Tech Vasc Interv Radiol 15 : 241-253, 2012
PubMed
23) Kiyosue H et al : Transcatheter obliteration of gastric varices. Part 1. Anatomic classification. Radiographics 23 : 911-920, 2003
PubMed
24) Hirota S et al : Retrograde transvenous obliteration of gastric varices. Radiology 211 : 349-356, 1999
PubMed
25) Park JK et al : Balloon-occluded retrograde transvenous obliteration (BRTO) for treatment of gastric varices : Review and meta-analysis. Dig Dis Sci 60 : 1543-1553, 2015
PubMed
26) Saad WE et al : Balloon-occluded retrograde transvenous obliteration of gastric varices. Cardiovasc Intervent Radiol 37 : 299-315, 2014
PubMed
27) Gwon DI et al : Gastric varices and hepatic encephalopathy : treatment with vascular plug and gelatin sponge-assisted retrograde transvenous obliteration--a primary report. Radiology 268 : 281-287, 2013
PubMed
28) Lee EW et al : Coil-assisted retrograde transvenous obliteration (CARTO) for the treatment of portal hypertensive variceal bleeding : Preliminary results. Clin Transl Gastroenterol 5 : e61, 2014
PubMed
29) Watanabe N et al : Current status of ectopic varices in Japan : Results of a survey by the Japan Society for Portal Hypertension. Hepatol Res 40 : 763-776, 2010
PubMed
30) 松井繁長ほか : 十二指腸静脈瘤の病態と治療方針. 日門亢会誌 21 : 19-25, 2015
 
31) Haruta I et al : Balloon-occluded retrograde transvenous obliteration (BRTO), a promising nonsurgical therapy for ectopic varices : a case report of successful treatment of duodenal varices by BRTO. Am J Gastroenterol 91 : 2594-2597, 1996
PubMed
32) Menu Y et al : Bleeding duodenal varices : diagnosis and treatment by percutaneous portography and transcatheter embolization. Gastrointest Radiol 12 : 111-113, 1987
PubMed
33) 佐藤隆啓ほか : 病態からみた門亢症のマネージメント 血行動態に応じた治療戦略 直腸静脈瘤. 消内視鏡 25 : 1840-1850, 2013
 
34) 千田剛士ほか : 肝外門脈閉塞にともなう胆管空腸吻合部静脈瘤破裂に対してα-cyanoacrylate monomerを用いた内視鏡的止血術が奏効した1例. 日消誌 107 : 1661-1668, 2010
Medical*Online
35) Moncure AC et al : Gastrointestinal hemorrhage from adhesion-related mesenteric varices. Ann Surg 183 : 24-29, 1976
PubMed
36) 滝川一ほか : 門脈血行異常症ガイドライン 2018年改訂版 (2018年12月13日 Version), 厚生労働科学研究費補助金 (難治性疾患政策研究事業) 「難治性の肝・胆道疾患に関する調査研究」班 : 門脈血行異常症分科会, 2018
 
37) 日本消化器病学会, 日本肝臓学会 (編) : 肝硬変診療ガイドライン 2020 改訂第3版, 南江堂, 61, 2020
 
P.50 掲載の参考文献
1) European Association for the Study of the Liver : EASL Clinical Practice Guidelines : Vascular diseases of the liver. J Hepatol 64 : 179-202, 2016
 
2) DeLeve LD et al : Vascular disorders of the liver. Hepatology 49 : 1729-1764, 2009
PubMed
3) Lisman T et al : Established and new-generation antithrombotic drugs in patients with cirrhosis-possibilities and caveats. J Hepatol 59 : 358-366, 2013
PubMed
4) Yerdel MA et al : Portal vein thrombosis in adults undergoing liver transplantation : risk factors, screening, management, and outcome. Transplantation 69 : 1873-1881, 2000
PubMed
5) de Franchis R ed : Portal Hypertension V : Proceedings of the Fifth Baveno International Consensus Workshop, 5th ed, Wiley-Blackwell, 156-157, 2011
 
6) Northup PG et al : Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease : 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 73 : 366-413, 2021
 
7) Hidaka H et al : Antithrombin III for portal vein thrombosis in patients with liver disease : A randomized, double-blind, controlled trial. Hepatol Res 48 : E107-E116, 2018
PubMed
8) Nagaoki Y et al : Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res 48 : 51-58, 2018
PubMed
9) 小嶋清一郎ほか : 本邦における門脈血栓症の実態 : 全国アンケート調査結果より. 日門亢会誌 22 : 176-189, 2016
 
10) Villa E et al : Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 143 : 1253-1260.e4, 2012
 
11) Delgado MG et al : Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 10 : 776-783, 2012
PubMed
12) European Association for the Study of the Liver (EASL) : EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol 65 : 146-181, 2016
 
13) 長沖祐子ほか : 門脈血栓症に対するエドキサバン療法. 肝胆膵 81 : 511-516, 2020
Medical*Online
P.59 掲載の参考文献
1) 高橋善弥太 : 劇症肝炎の全国集計-初発症状からみた意識障害発現までの日数と予後および定義の検討. 第12回犬山シンポジウム. A型肝炎・劇症肝炎, 中外医学社, 116-125, 1982
 
2) Vilstrup H et al : Hepatic encephalopathy in chronic liver disease : 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 60 : 715-735, 2014
 
3) Sharma P et al : Minimal hepatic encephalopathy in patients with cirrhosis by measuring liver stiffness and hepatic venous pressure gradient. Saudi J Gastroenterol 18 : 316-321, 2012
PubMed
4) Yoshiji H et al : Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res 51 : 725-749, 2021
PubMed
5) 日本肝臓学会 (編) : 慢性肝炎・肝硬変の診療ガイド 2019, 文光堂, 2019
 
6) Kawaguchi T et al : Rifaximin-altered gut microbiota components associated with liver/neuropsychological functions in patients with hepatic encephalopathy : An exploratory data analysis of phase II/III clinical trials. Hepatol Res 49 : 404-418, 2019
PubMed
7) Suzuki H et al : Real-world effects of long-term rifaximin treatment for Japanese patients with hepatic encephalopathy. Hepatol Res 49 : 1406-1413, 2019
PubMed
8) Fujita M et al : Skeletal muscle volume loss among liver cirrhosis patients receiving levocarnitine predicts poor prognosis. Medicine (Baltimore) 99 : e21061, 2020
PubMed
9) Katayama K et al : Effect of zinc on liver cirrhosis with hyperammonemia : a preliminary randomized, placebo-controlled double-blind trial. Nutrition 30 : 1409-1414, 2014
PubMed
10) Simon-Talero M et al : Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis. Gastroenterology 154 : 1694-1705.e4, 2018
 
11) Kumamoto M et al : Long-term results of balloon-occluded retrograde transvenous obliteration for gastric fundal varices : hepatic deterioration links to portosystemic shunt syndrome. J Gastroenterol Hepatol 25 : 1129-1135, 2010
PubMed
12) Saad WE : Portosystemic shunt syndrome and endovascular management of hepatic encephalopathy. Semin Intervent Radiol 31 : 262-265, 2014
PubMed
13) Saad WE et al : Balloon-occluded retrograde transvenous obliteration of gastric varices. Cardiovasc Intervent Radiol 37 : 299-315, 2014
PubMed
14) Laleman W et al : Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy : a multicenter survey on safety and efficacy. Hepatology 57 : 2448-2457, 2013
PubMed
15) Mukund A et al : Efficacy of balloon-occluded retrograde transvenous obliteration of large spontaneous lienorenal shunt in patients with severe recurrent hepatic encephalopathy with foam sclerotherapy : initial experience. J Vasc Interv Radiol 23 : 1200-1206, 2012
PubMed
16) Nishida S et al : Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese. World J Hepatol 11 : 531-541, 2019
PubMed
17) Ishikawa T et al : Liver stiffness measured by transient elastography as predictor of prognoses following portosystemic shunt occlusion. J Gastroenterol Hepatol 34 : 215-223, 2019
PubMed
P.65 掲載の参考文献
1) Yoshiji H et al : Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res 51 : 725-749, 2021
PubMed
2) European Association for the Study of the Liver : EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 69 : 406-460, 2018
 
3) Runyon BA et al : The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 117 : 215-220, 1992
 
4) Gupta R et al : Diagnosing ascites : value of ascitic fluid total protein, albumin, cholesterol, their ratios, serum-ascites albumin and cholesterol gradient. J Gastroenterol Hepatol 10 : 295-299, 1995
PubMed
5) Heuman DM et al : Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 40 : 802-810, 2004
PubMed
6) Tito L et al : Recurrence of spontaneous bacterial peritonitis in cirrhosis : frequency and predictive factors. Hepatology 8 : 27-31, 1988
PubMed
7) Abdel-Razik A et al : Ascitic fluid calprotectin and serum procalcitonin as accurate diagnostic markers for spontaneous bacterial peritonitis. Gut Liver 10 : 624-631, 2016
PubMed
8) Dibas M et al : Ascitic calprotectin for the diagnosis of spontaneous bacterial peritonitis : a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 32 : 1075-1083, 2020
PubMed
9) 日本消化器病学会, 日本肝臓学会 (編) : 肝硬変診療ガイドライン 2020 改訂第3版, 南江堂, 2020
 
10) Graziotto A et al : Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Dig Dis Sci 42 : 1708-1714, 1997
PubMed
11) Runyon BA : Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 57 : 1651-1653, 2013
 
12) 平方敦史ほか : 腹水管理の最近の進歩 4. 難治性腹水に対する治療法の選択-腹水濾過濃縮再静注法, 経静脈的肝内門脈短絡路, 腹腔静脈シャントの長所, 短所と適応について-. 肝臓 58 : 91-96, 2017
 
13) Lv XY et al : Rifaximin improves survival in cirrhotic patients with refractory ascites : A real-world study. World J Gastroenterol 26 : 199-218, 2020
PubMed
14) Di Pascoli M et al : Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. Liver Int 39 : 98-105, 2019
PubMed
15) Will V et al : Current treatment options of refractory ascites in liver cirrhosis-A systematic review and meta-analysis. Dig Liver Dis S1590-8658 (21) 00894-X, 2022
 
16) Kozaki K et al : Cell-free and concentrated ascites reinfusion therapy for decompensated liver cirrhosis. Ther Apher Dial 20 : 376-382, 2016
PubMed
P.73 掲載の参考文献
1) D'Amico G et al : Natural history of congestive gastropathy in cirrhosis. The Liver Study Group of V. Cervello Hospital. Gastroenterology 99 : 1558-1564, 1990
PubMed
2) Taor RE et al : Gastritis gastroendoscopic and microscopic. Endoscopy 7 : 209-215, 1975
 
3) McCormack TT et al : Gastric lesions in portal hypertension : inflammatory gastritis or congestive gastropathy? Gut 26 : 1226-1232, 1985
PubMed
4) Toyonaga A et al : Endoscopic, histologic and haemodynamic studies on portal hypertensive gastric mucosa. J Gastroenterol Hepatol 4 Suppl 1 : 132-135, 1989
 
5) Iwao T et al : Portal-hypertensive gastropathy develops less in patients with cirrhosis and fundal varices. J Hepatol 26 : 1235-1241, 1997
PubMed
6) Ohta M et al : Portal and gastric mucosal hemodynamics in cirrhotic patients with portal-hypertensive gastropathy. Hepatology 20 : 1432-1436, 1994
PubMed
7) 西崎泰弘ほか : 門脈圧亢進症性胃症. 日門亢会誌 16 : 56-68, 2010
 
8) Nishino K et al : Portal hypertensive gastropathy in liver cirrhosis : prevalence, natural history, and risk factors. Intern Med 61 : 605-613, 2022
PubMed
9) Migoh S et al : Role of endothelin-1 in congestive gastropathy in portal hypertensive rats. J Gastroenterol Hepatol 15 : 142-147, 2000
PubMed
10) Balan KK et al : The effects of Helicobacter pylori colonization on gastric function and the incidence of portal hypertensive gastropathy in patients with cirrhosis of the liver. Am J Gastroenterol 91 : 1400-1406, 1996
PubMed
11) 西崎泰弘ほか : 門脈圧亢進症性胃症 (Portal hypertensive gastropathy : PHG). 消臨 6 : 541-550, 2003
 
12) 北野善郎ほか : 門脈圧亢進症性胃症におけるH. pylori感染. 消化器科 26 : 636-641, 1998
 
13) 林星舟ほか : PHGとGAVEの内視鏡診断. 日門亢会誌 13 : 112-116, 2007
 
14) Furuichi Y et al : Discrimination between portal hypertensive gastropathy and Helicobacter pylori-related gastritis. Intern Med 61 : 601-603, 2022
PubMed
15) Perez-Ayuso RM et al : Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet 337 : 1431-1434, 1991
PubMed
16) Panes J et al : Effects of propranolol on gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Hepatology 17 : 213-218, 1993
PubMed
17) Panes J et al : Reduction of gastric hyperemia by glypressin and vasopressin administration in cirrhotic patients with portal hypertensive gastropathy. Hepatology 19 : 55-60, 1994
 
18) Li MK et al : Somatostatin reduces gastric mucosal blood flow in patients with portal hypertensive gastropathy : a randomized, double-blind crossover study. Dig Dis Sci 41 : 2440-2446, 1996
PubMed
19) Wagatsuma Y et al : Clinical usefulness of the angiotensin II receptor antagonist losartan in patients with portal hypertensive gastropathy. Hepatogastroenterology 53 : 171-174, 2006
PubMed
20) El Shahawy MS et al : The efficacy of argon plasma coagulation versus carvedilol for treatment of portal hypertensive gastropathy. Digestion 101 : 651-658, 2020
PubMed
21) Orloff MJ et al : Treatment of bleeding from portal hypertensive gastropathy by portacaval shunt. Hepatology 21 : 1011-1017, 1995
PubMed
22) Matsui O et al : A new coaxial needle system, hepatic artery targeting wire, and biplane fluoroscopy to increase safety and efficacy of TIPS. Cardiovasc Intervent Radiol 17 : 343-346, 1994
PubMed
23) Mezawa S et al : Effect of transjugular intrahepatic portosystemic shunt formation on portal hypertensive gastropathy and gastric circulation. Am J Gastroenterol 96 : 1155-1159, 2001
PubMed
24) Miyaaki H et al : Portal hypertensive gastropathy with portal thrombosis successfully treated with partial splenic embolization. Clin J Gastroenterol 2 : 218-221, 2009
PubMed
25) Shimizu T et al : Bleeding portal-hypertensive gastropathy managed successfully by partial splenic embolization. Hepatogastroenterology 49 : 947-949, 2002
PubMed
26) Ohmagari K et al : Effects of transcatheter splenic arterial embolization on portal hypertensive gastric mucosa. Am J Gastroenterol 88 : 1837-1841, 1993
PubMed
P.82 掲載の参考文献
1) Peck-Radosavljevic M : Thrombocytopenia in chronic liver disease. Liver Int 37 : 778-793, 2017
PubMed
2) Yoshida M et al : Changes in platelet counts and thrombocytopenia risk in patients with chronic liver disease with different etiologies using real-world Japanese data. Adv Ther 39 : 992-1003, 2022
PubMed
3) Hidaka H et al : Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenia undergoing invasive procedures. Clin Gastroenterol Hepatol 17 : 1192-1200, 2019
PubMed
4) Yoshiji H et al : Treatment algorithm for thrombocytopenia in patients with chronic liver disease undergoing planned invasive procedures. Hepatol Res 51 : 1181-1195, 2021
PubMed
5) Ohta M et al : Analysis of risk factors for massive intraoperative bleeding during laparoscopic splenectomy. J Hepatobiliary Pancreat Surg 12 : 433-437, 2005
PubMed
6) Yoshida H et al : Partial splenic embolization. Hepatol Res 38 : 225-233, 2008
PubMed
7) Buechter M et al : Partial spleen embolization reduces the risk of portal hypertension-induced upper gastrointestinal bleeding in patients not eligible for TIPS implantation. PLoS One 12 : e0177401, 2017
 
8) 日本IVR学会 (編) : 門脈圧亢進症診療における部分脾動脈塞栓術 (PSE) の手技に関するガイドライン 2021年度版. https://www.jsir.or.jp/docs/guideline/pse2021.pdf (閲覧2022年6月)
 
9) Ogawa S et al : Splenic vein diameter is a risk factor for the portal venous system thrombosis after partial splenic artery embolization. Cardiovasc Intervent Radiol 44 : 921-930, 2021
PubMed
10) Noguchi H et al : Changes in platelet kinetics after a partial splenic arterial embolization in cirrhotic patients with hypersplenism. Hepatology 22 : 1682-1688, 1995
PubMed
11) Hayashi H et al : Large splenic volume may be a useful predictor for partial splenic embolization-induced liver functional improvement in cirrhotic patients. J Hepatobiliary Pancreat Sci 21 : 51-57, 2014
PubMed
12) Lee CM et al : Evaluation of the effect of partial splenic embolization on platelet values for liver cirrhosis patients with thrombocytopenia. World J Gastroenterol 13 : 619-622, 2007
PubMed
13) Ishikawa T et al : Short-term effects of hepatic arterial buffer responses induced by partial splenic embolization on the hepatic function of patients with cirrhosis according to the Child-Pugh classification. Intern Med 60 : 1331-1342, 2021
 
14) Nagasue N et al : Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis. Hepatology 31 : 1107-1114, 2000
PubMed
15) Akahoshi T et al : Role of the spleen in liver fibrosis in rats may be mediated by transforming growth factor beta-1. J Gastroenterol Hepatol 17 : 59-65, 2002
PubMed
16) Tajiri T et al : Long-term hematological and biochemical effects of partial splenic embolization in hepatic cirrhosis. Hepatogastroenterology 49 : 1445-1448, 2002
PubMed
17) Sockrider CS et al : Partial splenic embolization for hypersplenism before and after liver transplantation. Clin Transplant 16 Suppl 7 : 59-61, 2002
 
18) Hansen K et al : Asplenic-hyposplenic overwhelming sepsis : postsplenectomy sepsis revisited. Pediatr Dev Pathol 4 : 105-121, 2001
PubMed
19) King H et al : Splenic studies. I. Susceptibility to infection after splenectomy performed in infancy. Ann Surg 136 : 239-242, 1952
PubMed
20) Waghorn DJ : Overwhelming infection in asplenic patients : current best practice preventive measures are not being followed. J Clin Pathol 54 : 214-218, 2001
 
21) Di Sabatino A et al : Post-splenectomy and hyposplenic states. Lancet 378 : 86-97, 2011
PubMed
22) Maddison FE : Embolic therapy of hypersplenism. Invest Radiol 8 : 280-300, 1973
 
23) Spigos DG et al : Partial splenic embolization in the treatment of hypersplenism. AJR Am J Roentgenol 132 : 777-782, 1979
PubMed
24) Ishikawa T et al : Concurrent partial splenic embolization with transcatheter arterial chemoembolization for hepatocellular carcinoma can maintain hepatic functional reserve. Hepatol Res 44 : 1056-1061, 2014
PubMed
25) Ishikawa T et al : Prevalence of Howell-Jolly bodies caused by partial splenic embolization for portal hypertension. Intern Med 52 : 1765-1768, 2013
PubMed
P.88 掲載の参考文献
1) Simonneau G et al : Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62 25 Suppl : D34-41, 2013
 
2) 日本循環器学会 : 肺高血圧症治療ガイドライン (2017年改訂版). https://plaza.umin.ac.jp/~jscvs/wordpress/wp-content/uploads/2020/06/JCS2017_fukuda_h.pdf (閲覧2022年8月)
 
3) Li J et al : Prevalence and prognosis of portopulmonary hypertension in 223 liver transplant recipients. Can Respir J 2018 : 9629570, 2018
PubMed
4) Simonneau G et al : Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53 : 1801913, 2019
PubMed
5) Johnson PJ et al : Assessment of liver function in patients with hepatocellular carcinoma : a new evidence-based approach-the ALBI grade. J Clin Oncol 33 : 550-558, 2015
 
6) Herve P et al : Pulmonary vascular disorders in portal hypertension. Eur Respir J 11 : 1153-1166, 1998
PubMed
7) Atsukawa M et al : Prevalence and characteristics of portopulmonary hypertension in cirrhotic patients who underwent both hepatic vein and pulmonary artery catheterization. Hepatol Res 50 : 1244-1254, 2020
PubMed
8) Kawaguchi T et al : Association between the albumin-bilirubin (ALBI) score and severity of portopulmonary hypertension (PoPH) : A data-mining analysis. Hepatol Res 51 : 1207-1218, 2021
PubMed
9) Swanson KL et al : Survival in portopulmonary hypertension : Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 8 : 2445-2453, 2008
 
10) Le Pavec J et al : Portopulmonary hypertension : survival and prognostic factors. Am J Respir Crit Care Med 178 : 637-643, 2008
PubMed
11) Krowka MJ et al : Portopulmonary hypertension : a report from the US-based REVEAL Registry. Chest 141 : 906-915, 2012
PubMed
12) Ishikawa T et al : Screening for portopulmonary hypertension using computed tomography-based measurements of the main pulmonary artery and ascending aorta diameters in patients with portal hypertension. Hepatol Res 52 : 255-268, 2022
PubMed
13) Kawut SM et al : Clinical risk factors for portopulmonary hypertension. Hepatology 48 : 196-203, 2008
PubMed
14) Provencher S et al : Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 130 : 120-126, 2006
PubMed
15) Benjaminov FS et al : Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 52 : 1355-1362, 2003
PubMed
16) Austin MJ et al : Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Liver Transpl : 287-291, 2008
PubMed
17) Krowka MJ et al : Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 6 : 443-450, 2000
PubMed
18) Huonker M et al : Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 44 : 743-748, 1999
PubMed
19) Savale L et al : Portopulmonary hypertension in the current era of pulmonary hypertension management. J Hepatol 73 : 130-139, 2020
 
20) Sakuma M et al : Portopulmonary hypertension : hemodynamics, pulmonary angiography, and configuration of the heart. Circ J 69 : 1386-1393, 2005
PubMed
21) Sahay S et al : Causes and circumstances of death in portopulmonary hypertension. Transplant Direct 7 : e710, 2021
PubMed
P.96 掲載の参考文献
1) Lok AS et al : Antiviral therapy for chronic hepatitis B viral infection in adults : A systematic review and meta-analysis. Hepatology 63 : 284-306, 2016
PubMed
2) Jang JW et al : Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology 61 : 1809-1820, 2015
PubMed
3) Nagaoki Y et al : Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos (t) ide analogs for hepatitis B virus-related cirrhosis. Hepatol Res 48 : 264-274, 2018
PubMed
4) Tamai H et al : Combination with portosystemic shunt occlusion and antiviral therapy improves prognosis of decompensated cirrhosis. JGH Open 4 : 670-676, 2020
PubMed
5) Toyoda H et al : Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology 67 : 505-513, 2018
PubMed
6) Kobayashi M et al : Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol 89 : 476-483, 2017
PubMed
7) Asahina Y et al : α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 58 : 1253-1262, 2013
 
8) Nagaoki Y et al : Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. Hepatol Res 50 : 1222-1233, 2020
PubMed
9) Tsuji S et al : Involvement of portosystemic shunts in impaired improvement of liver function after direct-acting antiviral therapies in cirrhotic patients with hepatitis C virus. Hepatol Res 50 : 512-523, 2020
PubMed
10) Takehara T et al : Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis : an open-label phase 3 trial. J Gastroenterol 54 : 87-95, 2019
 
11) Tahata Y et al : Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. J Gastroenterol 57 : 120-132, 2022
PubMed
12) Lens S et al : Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. J Hepatol 73 : 1415-1424, 2020
PubMed
13) Nagaoki Y et al : Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis. J Gastroenterol 48 : 847-855, 2013
 
14) 榎本平之ほか : セッションの概要について. 日本肝臓学会ほか (監), 上野義之ほか (編), 肝硬変の成因別実態 2018, 医学図書出版, 1-2, 2019
 
15) Gao B et al : Alcoholic liver disease : pathogenesis and new therapeutic targets. Gastroenterology 141 : 1572-1585, 2011
PubMed
16) Muntaner L et al : High doses of beta-blockers and alcohol abstinence improve long-term rebleeding and mortality in cirrhotic patients after an acute variceal bleeding. Liver Int 30 : 1123-1130, 2010
PubMed
17) Xie YD et al : Effect of abstinence from alcohol on survival of patients with alcoholic cirrhosis : A systematic review and meta-analysis. Hepatol Res 44 : 436-449, 2014
PubMed
18) Nagaoki Y et al : Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma : single-institution 20-year study. BMC Gastroenterol 21 : 306, 2021
PubMed
19) Abraham SC et al : Liver transplantation in precirrhotic biliary tract disease : Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. Am J Surg Pathol 30 : 1454-1461, 2006
PubMed
20) 滝川一ほか : 原発性胆管炎 (PBC) の診療ガイドライン (2017年) 2017年3月, 厚生労働科学研究費補助金 (難治性疾患政策研究事業) 「難治性の肝・胆道疾患に関する調査研究」班, 2017
 
21) Moctezuma-Velazquez C et al : Non-invasive prediction of high-risk varices in patients with primary biliary cholangitis and primary sclerosing cholangitis. Am J Gastroenterol 114 : 446-452, 2019
PubMed
22) Gores GJ et al : Prospective evaluation of esophageal varices in primary biliary cirrhosis : development, natural history, and influence on survival. Gastroenterology 96 : 1552-1559, 1989
PubMed
P.100 掲載の参考文献
1) Unger LW et al : Management of portal hypertension before and after liver transplantation. Liver Transpl 24 : 112-121, 2018
PubMed
2) Kiritani S et al : A selective oral vasopressin V2-receptor antagonist for patients with end-stage liver disease awaiting liver transplantation : a preliminary study. Biosci Trends 13 : 189-196, 2019
PubMed
3) 日本臓器移植ネットワーク : 臓器移植に関する提供件数と移植件数 (2022年). https://www.jotnw.or.jp/data/offer.php (閲覧2022年6月)
 
4) 日本肝臓学会 : 肝細胞癌の脳死肝移植に関する適応基準と選択基準の改訂について. https://www.jsh.or.jp/medical/news/2019/0701_01.html (閲覧2022年6月)
 
5) Merion RM et al : The survival benefit of liver transplantation. Am J Transplant 5 : 307-313, 2005
PubMed
6) Luo X et al : MELD as a metric for survival benefit of liver transplantation. Am J Transplant 18 : 1231-1237, 2018
PubMed
7) 日本肝臓学会 : 肝予備能評価スコア計算サイト (mALBIグレード追加) のご案内. https://www.jsh.or.jp/medical/guidelines/medicalinfo/hepatic_reserve.html (閲覧2022年6月)
 
8) 日本肝移植学会 : 肝移植症例登録報告. 移植 56 : 217-233, 2021
Medical*Online
9) Yerdel MA et al : Portal vein thrombosis in adults undergoing liver transplantation : risk factors, screening, management, and outcome. Transplantation 69 : 1873-1881, 2000
PubMed
10) Kawaguchi Y et al : Perceptions of post-transplant recidivism in liver transplantation for alcoholic liver disease. World J Hepatol 6 : 812-817, 2014
PubMed

第4章 各種原因における門脈圧亢進症への対策

P.105 掲載の参考文献
1) 杉浦光雄 : 病因と症状. 現代外科学大系 (40A) 門脈・副腎, 中山書店, 35-140, 1970
 
2) Ohfuji S et al : Japanese periodical nationwide epidemiologic survey of aberrant portal hemodynamics. Hepatol Res 49 : 890-901, 2019
PubMed
3) Okuda H et al : Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol 22 : 1-9, 1995
PubMed
4) Kageyama K et al : The albumin-bilirubin score detects changes in the liver function during treatment for Budd-Chiari syndrome : A retrospective observational study. Intern Med 61 : 959-967, 2022
PubMed
5) 滝川一ほか : 門脈血行異常症ガイドライン 2018年改訂版 (2018年12月13日 Version), 厚生労働科学研究費補助金 (難治性疾患政策研究事業) 「難治性の肝・胆道疾患に関する調査研究」班 : 門脈血行異常症分科会, 2018
 
6) Ren W et al : Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome : a systematic review. Eur J Gastroenterol Hepatol 25 : 830-841, 2013
PubMed
P.108 掲載の参考文献
1) Tohyama O et al : Antitumor activity of lenvatinib (e7080) : an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014 : 638747, 2014
PubMed
2) Kudo M et al : Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3 non-inferiority trial. Lancet 391 : 1163-1173, 2018
PubMed
3) Ohkubo H et al : VEGFR1-positive macrophages facilitate liver repair and sinusoidal reconstruction after hepatic ischemia/reperfusion injury. PLoS One 9 : e105533, 2014
PubMed
4) Mejias M et al : Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 49 : 1245-1256, 2009
PubMed
5) Hidaka H et al : Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma : a prospective cohort study. J Gastroenterol 47 : 1030-1035, 2012
PubMed
6) Hidaka H et al : Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma : A prospective cohort study. Hepatol Res 50 : 1083-1090, 2020
PubMed
7) Ikeda K et al : Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 52 : 512-519, 2017
PubMed
8) Ohya K et al : Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy. Sci Rep 9 : 12101, 2019
PubMed
P.110 掲載の参考文献
1) DeLeve LD et al : Toxic injury to hepatic sinusoids : sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 22 : 27-42, 2002
PubMed
2) 重福隆太ほか : 大腸癌化学療法中に食道胃静脈瘤破裂をきたした2症例. 日消誌 111 : 2326-2336, 2014
Medical*Online
3) Rubbia-Brandt L et al : Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15 : 460-466, 2004
PubMed
4) McDonald GB et al : Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation : a cohort study of 355 patients. Ann Intern Med 118 : 255-267, 1993
PubMed
5) Mohty M et al : Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients : a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 51 : 906-912, 2016
PubMed
6) Ohashi K et al : The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 64 : 32-38, 2000
PubMed
7) Tay J et al : Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 13 : 206-217, 2007
PubMed
P.113 掲載の参考文献
1) Yakushijin K et al : Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation : Incidence, risk factors and outcomes. Bone Marrow Transplant 51 : 403-409, 2016
PubMed
2) Carreras E et al : The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant 46 : 1495-1502, 2011
PubMed
3) McDonald GB et al : Venocclusive disease of the liver after bone marrow transplantation : diagnosis, incidence, and predisposing factors. Hepatology 4 : 116-122, 1984
PubMed
4) McDonald GB et al : Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation : a cohort study of 355 patients. Ann Intern Med 118 : 255-267, 1993
PubMed
5) Jones RJ et al : Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 44 : 778-783, 1987
PubMed
6) Mohty M et al : Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients : a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 51 : 906-912, 2016
PubMed
7) Corbacioglu S et al : Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients : a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant 53 : 138-145, 2018
PubMed
8) Nishida M et al : Novel ultrasonographic scoring system of sinusoidal obstruction syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 24 : 1896-1900, 2018
PubMed
9) 令和2 学会年度日本造血・免疫細胞療法学会ガイドライン委員会 (編) : 造血細胞ガイドライン SOS/TA-TMA (第2版), 日本造血・免疫細胞療法学会, 2022
 

第5章 今後の課題 - Where is "Point of no return" を求めて -

P.117 掲載の参考文献
1) 豊永純ほか : B-RTOの側面. 日門亢会誌 7 : 122-128, 2001
 
2) Di Marco V et al : Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension. Gastroenterology 151 : 130-139.e2, 2016
 
3) Lens S et al : Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology 153 : 1273-1283.e1, 2017
 
4) 國分茂博 : 門脈圧亢進症の現状と未来-本邦から海外に向けての発信-. 日消誌 116 : 363-373, 2019
Medical*Online
5) Tsuji S et al : Involvement of portosystemic shunts in impaired improvement of liver function after direct-acting antiviral therapies in cirrhotic patients with hepatitis C virus. Hepatol Res 50 : 512-523, 2020
PubMed
6) Ishikawa T et al : Liver stiffness measured by transient elastography as predictor of prognoses following portosystemic occlusion. J Gastroenterol Hepatol 34 : 215-223, 2019
PubMed
7) Gantumur D et al : Hepatic stellate cell a Mac-2-binding protein-producing cell in patient with liver fibrosis. Hepatol Res 51 : 1058-1063, 2021
PubMed
8) Faillaci F et al : Liver angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after hepatitis C virus direct-acting antivirals. Hepatology 68 : 1010-1024, 2018
PubMed
9) Kawagishi N et al : High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C. Hepatol Res 50 : 671-681, 2020
PubMed
10) Nakazawa M et al : Balloon-occluded retrograde transvenous obliteration as a procedure to improve liver function in patients with decompensated cirrhosis. JGH Open 1 : 127-133, 2017
PubMed
11) 持田智 : SVR後に門脈圧亢進症は改善するのか? 消化器内科 3 : 59-62, 2021
 
12) Simon-Talero M et al : Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis. Gastroenterology 154 : 1694-1705.e4, 2018
 
13) Kumamoto M et al : Long-term results of balloon-occluded retrograde transvenous obliteration for gastric fundal varices : hepatic deterioration links to portosystemic shunt syndrome. J Gastroenterol Hepatol 25 : 1129-1135, 2010
PubMed
14) 塚田一博 : 門脈圧亢進症における門脈域分水嶺. 北島政樹 (編), 消化器外科診療二頁の秘訣, 金原出版, 254-255, 2004
 

書評

最近チェックした商品履歴

Loading...